Host: David M. Simpson, MD Guest: David R. Walega, MD Guest: Eric J. Viel, MD, PhD Find the full Prescribing Information here. What are some of the current challenges in treating patients with painful diabetic peripheral neuropathy, and how can we overcome them? Explore those questions and more through the lens of patient case studies with Dr David M. Simpson, Dr Eric Viel, and Dr David Walega. Here to walk us through the clinical trial data that led to the FDA approval of a treatment option for painful diabetic peripheral neuropathy of the feet is Dr David M. Simpson, a Professor of Neurology at the Icahn School of Medicine and Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division at Mount Sinai in New York. QUTENZA® is a registered trademark of Averitas Pharma, Inc.© 2021 Averitas Pharma, Inc. All rights reserved.M-QZA-US-01-21-0060 July 2021

Medical Industry Feature

Case Studies Addressing Modern Care Challenges with Painful Diabetic Peripheral Neuropathy of the Feet

Host: Tracey Evans, MD Guest: Raja Mudad, MD For thirty years, there were limited therapeutic advancements leading to FDA approvals in extensive-stage small cell lung cancer (ES-SCLC). However, this all changed with the IMpower133 trial, which led to the emergence of immunotherapy as a first line treatment option in ES-SCLC. Joining Dr. Tracey Evans is medical oncologist Dr. Raja Mudad to discuss the IMpower133 trial and the reasons to consider TECENTRIQ® (atezolizumab), the first immunotherapy combination for patients with ES-SCLC. This program is intended for US Physicians. M-US-00010808(v1.0)

An Immunotherapy Combination as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Host: Jennifer Caudle, DO Guest: Michael Wechsler, MD In addition to understanding the definitions of severe asthma and uncontrolled asthma, it’s important for clinicians to be aware of the overall burden that severe asthma and uncontrolled asthma can impose on a patient’s life. So to help us better understand the severe asthma spectrum, Dr Jennifer Caudle is joined by Dr Michael Wechsler, Director of the Cohen Family Asthma Institute at National Jewish Health in Denver, Colorado. ©2021 Amgen. All rights reserved. US-53805 Last Updated 6/21 

Recognizing Patient Needs Across the Heterogeneous Spectrum of Severe Asthma

Host: Matt Birnholz, MD Guest: Jonathan Corren, MD As recent research demonstrates the important role that TSLP plays in asthma inflammation, Dr Matt Birnholz is joined by Dr Jonathan Corren, an Associate Clinical Professor of Medicine and Pediatrics at David Geffen School of Medicine in Los Angeles. Together, they review how TSLP acts across the spectrum of asthma inflammation, the correlation of TSLP with clinical features of asthma, and more. ©2021 Amgen. All rights reserved. US-53813 Last Updated 6/21

Understanding the Role of TSLP in Severe Asthma

Guest: David M. Simpson, MD Guest: Jon T. Gertken, MD Guest: Stephanie Simon, NP Find the full Prescribing Information here. There are multiple ways to incorporate the use of Qutenza, a topical treatment for painful diabetic peripheral neuropathy of the feet, into practice. Tune in to hear Dr. David M. Simpson, Dr. Jon T. Gertken, and Ms. Stephanie Simon share their best practices for administering Qutenza as well as the management of painful diabetic peripheral neuropathy of the feet. QUTENZA® is a registered trademark of Averitas Pharma, Inc.© 2021 Averitas Pharma, Inc. All rights reserved.M-QZA-US-01-21-0065 June 2021 

Best Practices for Administering Prescription Strength Capsaicin for Painful DPN of the Feet

Host: Jennifer Caudle, DO Guest: Tracey Evans, MD Small cell lung cancer (SCLC) is a highly aggressive, lethal, and widely metastatic lung cancer. While therapeutic progress in SCLC has been limited over the years, immunotherapy has made some meaningful advancements in the treatment landscape. Joining Dr. Jennifer Caudle to discuss key diagnostic and therapeutic considerations such as TECENTRIQ® (atezolizumab) for 1L ES-SCLC, is Dr. Tracey Evans, Director of Thoracic Oncology Research at Lankenau Institute for Medical Research and Co-Director of the Thoracic Oncology Program at Main Line Health. This program is intended for US Physicians. M-US-00010802(v1.0)

Reevaluating Outlooks for Small Cell Lung Cancer

Host: Joel Wedd MD, MPH Not only is hepatocellular carcinoma (HCC) the most common primary liver cancer in adults, but it’s also the fastest-growing cause of cancer-related deaths in the US. That’s why Dr. Joel Wedd, Associate Professor of Medicine at the Virginia Commonwealth University and Medical Director of Liver Transplant at the Hume-Lee Transplant Center, is here to discuss the pathogenesis of hepatocellular carcinoma, risk factors, the importance of early-stage detection, and more. 

Investigating the Rise of Liver Cancer

Guest: Brett Nowlan, MD Metabolic dysfunction is the central driver for conditions with some of the highest mortality rates. Identifying this dysfunction early on is essential to preventing disease progression. Dr. Brett Nowlan, a cardiologist at Cottage Grove Cardiology in West Hartford, Connecticut, explains why.

Recognizing Metabolic Dysfunction as a Driver of Cardiovascular Risk

Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.

hubhopper

Medical Industry Feature

hubhopper